Scilex (SCLX) Holding announced that the U.S. FDA has acknowledged the submission of our Supplemental New Drug Application, SNDA, for ELYXYB in acute pain indication.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
